News
Teos Therapeutics downgraded to Hold after belrestotug failure and GSK deal ending. Read my updated analysis on ITOS stock ...
Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...
6h
Zacks Investment Research on MSNGSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease DrugGSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston ...
In pharmaphorum's Digital and social media themed month, Daniel Ghinn explores GSK's use of social media and the milestones it has reached to achieve its current success in this space. "There's a ...
And for its part, GSK won't concede that Sirtris' small molecules don't bind the targets. In an e-mailed statement, Ad Rawcliffe, head of GSK's WorldWide Business Development group, says ...
GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker this morning. The fast ...
The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results